What Those Drug Maker Majors Have That Investors Like? - Sanofi, TherapeuticsMD, Heron Therapeutics, and Rockwell Medical

Wednesday, June 1, 2016 Drug News J E 4

NEW YORK, May 31, 2016 /PRNewswire/ --

The Major Drug Manufacturers industry continues to battle challenges in pricing, competition, and policies, but this has not slowed down a handful of stocks in this space from delivering remarkable results. Ahead of today's session, has issued technical alerts on the following Healthcare equities: Sanofi (NYSE: SNY), TherapeuticsMD Inc. (AMEX: TXMD), Heron Therapeutics Inc. (NASDAQ: HRTX), and Rockwell Medical Inc. (NASDAQ: RMTI). Learn how you can access the trading alerts for these stocks by clicking on the link below:

Sanofi's stock climbed 0.36%, finishing last Friday's session at $41.26 with a total volume of 883,625 shares traded. The Company researches, develops, manufactures, and markets various therapeutic solutions. Over the last month and the previous three months, shares of the Company have advanced 0.34% and 8.71%, respectively. Moreover, the stock has gained 0.81% on an YTD basis. The Company's shares are trading above their 50-day moving average by 3.09%. Additionally, shares of Sanofi have a Relative Strength Index (RSI) of 61.38. Do not lose out on any SNY's trade by activating your free access to the trade alerts now at:

On Friday, shares in TherapeuticsMD Inc. ended the session 1.62% higher at $8.80. The stock recorded a trading volume of 900,648 shares. The Company manufactures and distributes prescription and over-the-counter product lines, including prenatal vitamins, iron supplements, and natural menopause relief products under the vitaMedMD brand, as well as generic formulations of its prescription prenatal vitamins products under the BocaGreenMD Prena1 name. The Company's shares have gained 4.27% in the last month and 44.03% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 15.30% and 22.63%, respectively. Moreover, shares of TherapeuticsMD have an RSI of 68.68. Sign up for your trade alert on TXMD at:

California headquartered biotech Company, Heron Therapeutics Inc.'s stock saw a slight correction of 0.21%, to close the day at $19.16 with a total volume of 241,740 shares traded. The Company's shares have advanced 20.65% in the previous three months. The stock is trading 1.29% below its 50-day moving average. Additionally, shares of Heron Therapeutics have an RSI of 50.79. Register for free on and activate your trade alert on HRTX at:

Shares in Michigan-based integrated biopharma Company, Rockwell Medical Inc. recorded a trading volume of 268,024 shares, and ended Friday's session 0.86% higher at $9.35. The stock is trading above its 50-day and 200-day moving averages by 16.10% and 1.90%, respectively. The Company's shares have an RSI of 57.86. Trade alert on RMTI is available for free at:


Active Wall Street: 

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

AWS has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly at: Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom Email: Phone number: 1-858-257-3144

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Daiichi Sankyo Provides Update on HER3-Lung Study ...
Monkey Joe's Raises Funds for Childhood Cancer Res...